Jerusalem Pharmaceuticals Co. Ltd. announced unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported net income after tax of $1,188,800 or $0.066 per basic and diluted share compared to net income after tax of $1,605,998 or $0.089 per basic and diluted share reported in the same period last year. Sales were $8,418,052 against $8,406,019 reported last year. Net Income before tax was $1,190,386 against $1,607,756 reported last year. Net cash flow from operating activities was $879,656 against $1,629,424 reported last year. Purchase of property, plant and equipment was $239,841 against $693,716 reported last year. Purchase of intangible assets was $108,868.